Akili Interactive Labs, Inc. is a pioneering digital therapeutics company dedicated to developing video game-based treatments for neurological and psychiatric conditions. Founded in 2011 and headquartered in Boston, Massachusetts, Akili's mission is to merge medical-grade science with consumer-grade technology to create engaging and effective healthcare solutions. The company's flagship product, EndeavorRx, is the first FDA-cleared prescription video game designed to improve attention function in children with Attention Deficit Hyperactivity Disorder (ADHD).
Key Strategic Focus
Akili's strategic focus centers on developing and commercializing digital therapeutics that address cognitive deficiencies associated with various medical conditions. The company specializes in creating interactive, game-based treatments that target neural systems involved in attentional control and cognitive function. Utilizing proprietary technologies such as the Selective Stimulus Management Engine (SSME), Akili aims to deliver personalized and adaptive therapeutic experiences. The primary markets targeted include ADHD, major depressive disorder (MDD), autism spectrum disorder (ASD), and multiple sclerosis (MS).
Financials and Funding
As of July 2025, Akili Interactive Labs has raised a total of $110 million in funding over eight rounds, with the latest being a Series D round on May 26, 2021. The company went public on August 22, 2022, through a merger with Social Capital Suvretta Holdings Corp. I, a special purpose acquisition company (SPAC), resulting in a combined entity listed on Nasdaq under the ticker symbol "AKLI." The merger was valued at approximately $1 billion and generated $163 million in gross proceeds. As of June 2025, Akili's annual revenue reached $35 million.
Pipeline Development
Akili's product pipeline includes several key candidates:
- EndeavorRx: An FDA-cleared prescription video game designed to improve attention function in children aged 8 to 12 with ADHD.
- EndeavorOTC: An over-the-counter version of EndeavorRx tailored for adults with ADHD, available without a prescription.
- AKL-T01: A digital therapeutic under research for improving cognitive impairments, including potential treatment for COVID-19 related brain fog.
The company is also exploring applications in other cognitive conditions such as major depressive disorder, autism spectrum disorder, and multiple sclerosis.
Technological Platform and Innovation
Akili's innovation is underpinned by its proprietary technologies:
- Selective Stimulus Management Engine (SSME): Delivers specific sensory stimuli and motor challenges to target neural systems involved in attentional control.
- Body Brain Trainer (BBT): Integrates cognitive and physical training to target neural systems involved in attention, impulsivity, and working memory.
- Spatial Navigation Engine (SNAV): Designed to improve spatial navigation, memory, and planning through targeted cognitive challenges.
These platforms enable the development of personalized, adaptive, and engaging therapeutic experiences that are both effective and enjoyable for users.
Leadership Team
Akili's leadership comprises experienced professionals in neuroscience, technology, and business:
- Eddie Martucci: Co-founder and Chief Executive Officer, with a background in biotechnology and digital health.
- Adam Gazzaley: Co-founder and Chief Science Advisor, a renowned neuroscientist specializing in cognitive neuroscience.
- Matthew Omernick: Co-founder and Chief Creative Officer, with extensive experience in game design and development.
Their combined expertise drives Akili's mission to revolutionize digital therapeutics.
Leadership Changes
In recent developments, Akili appointed Matt Franklin as President and CEO, signaling a strategic shift in corporate direction. This change reflects the company's adaptability and commitment to leadership that aligns with its evolving vision.
Competitor Profile
Market Insights and Dynamics
The digital therapeutics market is experiencing significant growth, with projections indicating a valuation of $22.6 billion by 2025, growing at a CAGR of 19.4%. This expansion is driven by technological advancements and increasing demand for cost-effective healthcare solutions.
Competitor Analysis
Key competitors in the gamified healthcare solutions market include:
- Ayogo: Develops patient engagement solutions through gamification.
- Bunchball Inc.: Offers gamification platforms to drive user engagement.
- EveryMove, Inc.: Provides fitness incentive programs using gamification strategies.
- Fitbit, Inc.: Known for wearable fitness technology incorporating gamified elements.
These companies focus on enhancing patient engagement and health outcomes through interactive and motivational platforms.
Strategic Collaborations and Partnerships
Akili has established significant partnerships to strengthen its market position:
- Shionogi: In March 2019, Akili partnered with Shionogi to commercialize its digital medicines in Japan and Taiwan.
- TALi Digital: In August 2021, Akili licensed TALi Digital's technology to develop a new game-based treatment for improving early childhood attention.
- Roblox: In May 2022, Akili partnered with Roblox, allowing children using EndeavorRx for ADHD treatment to redeem rewards on the platform, enhancing user engagement.
Operational Insights
Akili's strategic considerations include:
- Market Position: As a pioneer in FDA-cleared digital therapeutics, Akili holds a competitive advantage in the digital health sector.
- Competitive Advantages: Proprietary technologies, strong clinical validation, and strategic partnerships position Akili favorably against competitors.
- Adaptability: The company's shift towards a direct-to-consumer model with products like EndeavorOTC demonstrates responsiveness to market dynamics.
Strategic Opportunities and Future Directions
Akili's strategic roadmap includes:
- Product Expansion: Developing new digital therapeutics for a broader range of cognitive conditions.
- Market Penetration: Expanding into international markets through partnerships and regulatory approvals.
- Technological Innovation: Enhancing existing platforms and exploring new technologies to improve therapeutic efficacy and user engagement.
Leveraging its current strengths, Akili is well-positioned to achieve these objectives and drive growth in the digital therapeutics industry.
Contact Information
- Website: www.akiliinteractive.com
- Headquarters: Boston, Massachusetts, United States
For more information, visit Akili's official website.
